Dr. Christopher F. Harris M.D.

Recommended Articles

• What is Tuberculosis?

  Tuberculosis, or TB, is a serious bacterial infection that often affects the lungs. It may also spread to other parts of the body, like the central nervous system, lymphatic system, and circulatory system. Treatment for tuberculosis may take a long time. The infectious organism may spread from one...

• Cystic Fibrosis Breakthrough in Left Ventricular Cardiac Disturbances

  Cystic fibrosis may be one of the most common autosomal recessive lethal diseases, but there remains much that is unknown about it. It has been established that the disease causes chronic pulmonary disease and is also capable of leading to cor pulmonale with right ventricular dysfunction, but it was...

• What are the Different Types of Inhalers Used to Treat Asthma?

  Managing medication and using inhalers have become integral parts of the asthma care routine. An inhaler allows you the freedom of carrying minute doses of medication for use in emergencies wherever you may go. It’s a huge relief knowing that help is immediately at hand in your trouser pocket. Not...

• Pulmonary Rehabilitation for Patients with COPD

  Patients who are diagnosed with chronic obstructive pulmonary disease (COPD) should expect mucus production that is tenacious, long-term coughing, and extreme fatigue. The main concern with COPD is if permanent scars have developed in the lungs. If scarring does occur, the condition cannot be cured...

• Firefighters from Around the World Take Steps Toward Cystic Fibrosis Research

  As a firefighter, Wes Loucks received countless emergency phone calls throughout his 32 years of service for the Portland Fire and Rescue Bureau. After retiring, he received a personal call for help from his own family. His two grandsons were both born with cystic fibrosis (CF), a chronic genetic...

• FDA Approves Orkambi to Treat Young Children with Cystic Fibrosis

  Orkambi is an oral drug developed by Vertex Pharmaceuticals and approved by the United States Food and Drug Administration (FDA) for the treatment of cystic fibrosis (CF) in certain patient groups. It is the second drug to be approved for use in patients with CF, after Kalydeco. ...